Postmortem Cortical Transcriptomics of Lewy Body Dementia Reveal Mitochondrial Dysfunction and Lack of Neuroinflammation.

[1]  L. Stefanis,et al.  Neuropsychiatric symptoms and α-Synuclein profile of patients with Parkinson’s disease dementia, dementia with Lewy bodies and Alzheimer’s disease , 2018, Journal of Neurology.

[2]  Jens Nielsen,et al.  Metabolic Network-Based Identification and Prioritization of Anticancer Targets Based on Expression Data in Hepatocellular Carcinoma , 2018, Front. Physiol..

[3]  I. Ferrer,et al.  Transcriptional network analysis in frontal cortex in Lewy body diseases with focus on dementia with Lewy bodies , 2018, Brain pathology.

[4]  I. McKeith,et al.  Molecular changes in the absence of severe pathology in the pulvinar in dementia with Lewy bodies , 2018, Movement disorders : official journal of the Movement Disorder Society.

[5]  Sonja W. Scholz,et al.  Investigating the genetic architecture of dementia with Lewy bodies: a two-stage genome-wide association study , 2018, The Lancet Neurology.

[6]  C. Taylor,et al.  Regulation of immunity and inflammation by hypoxia in immunological niches , 2017, Nature Reviews Immunology.

[7]  A. Martínez-Marcos,et al.  &agr;-Synucleinopathy in the Human Amygdala in Parkinson Disease: Differential Vulnerability of Somatostatin- and Parvalbumin-Expressing Neurons , 2017, Journal of neuropathology and experimental neurology.

[8]  D. Ffytche,et al.  New Therapeutic Strategies for Lewy Body Dementias , 2017, Current Neurology and Neuroscience Reports.

[9]  J. Freer.  UK lags far behind Europe on diagnosis of dementia with Lewy bodies , 2017, British Medical Journal.

[10]  Alan J. Thomas,et al.  Diagnosis and management of dementia with Lewy bodies , 2017, Neurology.

[11]  V. Turk,et al.  Lysosomal cathepsins and their regulation in aging and neurodegeneration , 2016, Ageing Research Reviews.

[12]  W. Sadee,et al.  Gene expression profiling of brain samples from patients with Lewy body dementia. , 2016, Biochemical and biophysical research communications.

[13]  G. Deuschl,et al.  Abolishing the 1‐year rule: How much evidence will be enough? , 2016, Movement disorders : official journal of the Movement Disorder Society.

[14]  W. Streit,et al.  Microglia in dementia with Lewy bodies , 2016, Brain, Behavior, and Immunity.

[15]  M. Stowell,et al.  Exosomes and other extracellular vesicles in neural cells and neurodegenerative diseases. , 2016, Biochimica et biophysica acta.

[16]  Paul Edison,et al.  Neuroinflammation in Alzheimer's disease: Current evidence and future directions , 2016, Alzheimer's & Dementia.

[17]  H. Kim,et al.  IDH2 deficiency promotes mitochondrial dysfunction and dopaminergic neurotoxicity: implications for Parkinson’s disease , 2016, Free radical research.

[18]  Jason J. Corneveaux,et al.  Next-generation profiling to identify the molecular etiology of Parkinson dementia , 2016, Neurology: Genetics.

[19]  J. O'Brien,et al.  Exome sequencing in dementia with Lewy bodies , 2016, Translational Psychiatry.

[20]  D. Aarsland,et al.  Neurocognitive Deficits Distinguishing Mild Dementia with Lewy Bodies from Mild Alzheimer's Disease are Associated with Parkinsonism. , 2016, Journal of Alzheimer's disease : JAD.

[21]  B. Boeve,et al.  Lewy body dementias , 2015, The Lancet.

[22]  D. Catalucci,et al.  Neutrophils promote Alzheimer's disease–like pathology and cognitive decline via LFA-1 integrin , 2015, Nature Medicine.

[23]  Qibin Li,et al.  Experimental validation of methods for differential gene expression analysis and sample pooling in RNA-seq , 2015, BMC Genomics.

[24]  B. Giometto,et al.  The possible involvement of mitochondrial dysfunctions in Lewy body dementia: a systematic review. , 2015, Functional neurology.

[25]  Janna H. Neltner,et al.  Disease-related microglia heterogeneity in the hippocampus of Alzheimer’s disease, dementia with Lewy bodies, and hippocampal sclerosis of aging , 2015, Acta Neuropathologica Communications.

[26]  Steven L Salzberg,et al.  HISAT: a fast spliced aligner with low memory requirements , 2015, Nature Methods.

[27]  B. Bogerts,et al.  VGF expression by T lymphocytes in patients with Alzheimer's disease , 2015, Oncotarget.

[28]  D. Dinsdale,et al.  RBM3 mediates structural plasticity and protective effects of cooling in neurodegeneration , 2014, Nature.

[29]  T. Hortobágyi,et al.  Regional Multiple Pathology Scores Are Associated with Cognitive Decline in Lewy Body Dementias , 2014, Brain pathology.

[30]  B. Mollenhauer,et al.  Biomarkers in biological fluids for dementia with Lewy bodies , 2014, Alzheimer's Research & Therapy.

[31]  B. Trapp,et al.  Microglial displacement of inhibitory synapses provides neuroprotection in the adult brain , 2014, Nature Communications.

[32]  W. M. van der Flier,et al.  Genetic analysis implicates APOE, SNCA and suggests lysosomal dysfunction in the etiology of dementia with Lewy bodies , 2014, Human molecular genetics.

[33]  K. Ülgen,et al.  Systematic analysis of transcription-level effects of neurodegenerative diseases on human brain metabolism by a newly reconstructed brain-specific metabolic network , 2014, FEBS open bio.

[34]  D. Aarsland,et al.  Long-Term Mortality in a Cohort of Home-Dwelling Elderly with Mild Alzheimer's Disease and Lewy Body Dementia , 2014, Dementia and Geriatric Cognitive Disorders.

[35]  D. Aarsland,et al.  The use and costs of formal care in newly diagnosed dementia: a three-year prospective follow-up study. , 2014, The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry.

[36]  Y. Bordelon,et al.  Dementia with Lewy Bodies , 2014, Seminars in Neurology.

[37]  Wei Shi,et al.  featureCounts: an efficient general purpose program for assigning sequence reads to genomic features , 2013, Bioinform..

[38]  C. Laske,et al.  Increased myeloperoxidase plasma levels in patients with Alzheimer's disease. , 2014, Journal of Alzheimer's disease : JAD.

[39]  K. Chopra,et al.  Granulocyte colony stimulating factor (GCSF) improves memory and neurobehavior in an amyloid-β induced experimental model of Alzheimer's disease , 2013, Pharmacology Biochemistry and Behavior.

[40]  I. Nookaew,et al.  Enriching the gene set analysis of genome-wide data by incorporating directionality of gene expression and combining statistical hypotheses and methods , 2013, Nucleic acids research.

[41]  Davis J. McCarthy,et al.  Count-based differential expression analysis of RNA sequencing data using R and Bioconductor , 2013, Nature Protocols.

[42]  Sean R. Davis,et al.  NCBI GEO: archive for functional genomics data sets—update , 2012, Nucleic Acids Res..

[43]  K. Wilhelmsen,et al.  Serum Granulocyte Colony-Stimulating Factor and Alzheimer's Disease , 2012, Dementia and Geriatric Cognitive Disorders Extra.

[44]  Jeffrey T. Leek,et al.  A statistical approach to selecting and confirming validation targets in -omics experiments , 2012, BMC Bioinformatics.

[45]  C. Cimino,et al.  Pilot study of granulocyte-colony stimulating factor for treatment of Alzheimer's disease. , 2012, Journal of Alzheimer's disease : JAD.

[46]  Jason A. Papin,et al.  TIGER: Toolbox for integrating genome-scale metabolic models, expression data, and transcriptional regulatory networks , 2011, BMC Systems Biology.

[47]  Jason A. Papin,et al.  Functional integration of a metabolic network model and expression data without arbitrary thresholding , 2011, Bioinform..

[48]  M. Heneka,et al.  Distinct modulation of microglial amyloid β phagocytosis and migration by neuropeptidesi , 2010, Journal of Neuroinflammation.

[49]  B. Hyman,et al.  Neuronal expression of myeloperoxidase is increased in Alzheimer's disease , 2004, Journal of neurochemistry.

[50]  P. Hof,et al.  Lewy body densities in the entorhinal and anterior cingulate cortex predict cognitive deficits in Parkinson's disease , 2003, Acta Neuropathologica.